Novartis: new developments in multiple sclerosis and oncology

This series of company profiles looks at some of the major players in the UK pharmaceutical industry, their current areas of expertise, and forthcoming products and initiatives that will have an impact on therapeutics and prescribing in the near future. In this article we provide an overview of Novartis and its current portfolio, and look at its pipeline of new drugs and areas of research interest. Copyright © 2010 John Wiley & Sons, Ltd.